DOW JONES27,246.59+165.23 0.61%
S&P 5003,151.35+23.14 0.74%
NASDAQ9,095.77+130.16 1.45%

Rubius Therapeutics Reports First Patient Dosed In Phase 1b Trial Of RTX-134 For Treatment Of Patients With Phenylketonuria

Benzinga · 01/30/2020 13:09